INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro(TM) for Early Alzheimer’s Disease
November 27, 2023
Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases
June 17, 2021
Related Post
-
-
Red White & Bloom Provides Update Relating to Aleafia Health
November 22, 2023
-
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
November 21, 2023
-
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
November 15, 2023